{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:20:36Z","timestamp":1763828436529,"version":"3.45.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As triple-negative breast cancer (TNBC) has a poorer prognosis when compared to hormone- and human epidermal growth factor 2-positive disease, it is vital to find treatments and schedules to improve outcomes inpatients with TNBC. The purpose of this study is to compare pathologic complete response (pCR) rates in early-stage TNBC between weekly versus every three-week carboplatin dosing with paclitaxel and pembrolizumab followed by dose-dense doxorubicin and cyclophosphamide (ddAC) and pembrolizumab in a modified KEYNOTE-522 regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, single-center review was conducted on patients who received both treatment and surgery at the James Cancer Hospital at The Ohio State University Medical Center (The James) for TNBC with carboplatin, paclitaxel, and pembrolizumab followed by ddAC and pembrolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 92 patients were included in this study; 51 patients received weekly carboplatin and 41 patients received every three-week carboplatin. The pCR rate at time of surgery was 47.1% in the weekly group and 70.1% (P\u2009=\u20090.03) for the every three-week group. Dose reductions of chemotherapy (35.3% vs. 26.8%) and dose delays of greater than 7\u2009days due to immunotherapy toxicities (23.5% vs. 14.6%) were greater in the weekly cohort. There were no differences in grade 3 or higher neutropenia between groups nor the use of granulocyte colony stimulating factor support. Infusion hypersensitivity reactions (iHSR) occurred in 19.6% of weekly patients and 4.9% of every three-week patients (P\u2009=\u20090.06).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-center analysis, every three-week carboplatin dosing followed by ddAC in a modified KEYNOTE-522 regimen provides higher pCR rates at the time of surgery. Patients who received weekly carboplatin dosing experienced more iHSR. These findings strongly warrant additional studies to determine the relationship of carboplatin dosing to TNBC outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf372","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:15:14Z","timestamp":1763558114000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of carboplatin schedule on pCR in a modified KEYNOTE-522 regimen with dose-dense AC for triple negative breast cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Kennedi G","family":"Satterfield","sequence":"first","affiliation":[{"name":"The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, Department of Pharmacy , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Berger","sequence":"additional","affiliation":[{"name":"The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, Department of Pharmacy , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Reed","sequence":"additional","affiliation":[{"name":"The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, Department of Pharmacy , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Center for Biostatistics , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Collins","sequence":"additional","affiliation":[{"name":"The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, Department of Pharmacy , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionisia","family":"Quiroga","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Division of Medical Oncology, The Stefanie Spielman Comprehensive Breast Center , Columbus, OH 43212,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"year":"2024","author":"U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool","key":"2025112211170582200_oyaf372-B1"},{"author":"Gradishar","key":"2025112211170582200_oyaf372-B2","first-page":"66"},{"key":"2025112211170582200_oyaf372-B3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112211170582200_oyaf372-B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early Triple-Negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112211170582200_oyaf372-B5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741\/cancer and leukemia group B trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025112211170582200_oyaf372-B6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112211170582200_oyaf372-B7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025112211170582200_oyaf372-B8","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025112211170582200_oyaf372-B9","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025112211170582200_oyaf372-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-024-00643-5","article-title":"Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer","volume":"10","author":"Mai","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2025112211170582200_oyaf372-B11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025112211170582200_oyaf372-B12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2025112211170582200_oyaf372-B13","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.3747\/co.21.1966","article-title":"Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations","volume":"21","author":"Boulanger","year":"2014","journal-title":"Curr Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf372\/65394931\/oyaf372.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf372\/65394931\/oyaf372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf372\/65394931\/oyaf372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:17:11Z","timestamp":1763828231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf372\/8328053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf372","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"oyaf372"}}